KR20190077714A - Lactobacillus plantarum KC28 having anti-obesity effect and uses thereof - Google Patents

Abstract

A Lactobacillus plantarum KC28 strain (Accession Number: KCTC13377BP) having an anti-obesity effect is disclosed. The Lactobacillus plantarum KC28 strain according to the present invention has an anti-obesity effect, and thus can be used to prevent obesity and metabolic diseases caused by obesity in modern people.

Description

Lactobacillus plantarum KC28 strain having anti-obesity effect and its use {Lactobacillus plantarum KC28 having anti-obesity effect and uses thereof}

The present invention relates to a Lactobacillus plantarum strain having an anti-obesity effect and a use thereof, and more particularly to a Lactobacillus plantarum KC28 strain having an anti-obesity effect, a probiotic preparation containing the same, Food compositions and pharmaceutical compositions.

Obesity is a major health problem in most countries. The World Health Organization (WHO) estimates that over one billion adults worldwide are overweight, and 300 million of them are clinically obese (Hotamisligil, 2006). Such obesity is a major risk factor for cardiovascular disease, stroke, insulin resistance, diabetes, liver disease, neurodegenerative diseases, respiratory diseases and other serious diseases, and is a risk factor for some cancers including breast and colon cancer . In addition, in addition to physical health effects, obesity causes depression, dietary habits, and low self esteem, which have a detrimental effect on quality of life and mental health.

Among these, the steady increase in food intake with high energy loads and the social changes associated with less exercise increase the incidence of obesity and obesity-induced metabolic diseases. However, conventional treatments based on low-calorie diets and exercises have little effect on obesity control and result in temporary weight loss.

Therefore, the development of a drug having an anti-obesity effect is urgently needed.

The present invention provides a Lactobacillus plantarum KC28 strain which can be used to inhibit the occurrence of metabolic diseases caused by obesity and obesity by having an anti-obesity effect derived from the above-mentioned demand.

Here, the KC28 strain can be isolated from the kimchi.

The Lactobacillus plantarum KC28 strain (Accession No .: KCTC13377BP) according to an embodiment of the present invention is characterized by having an anti-obesity effect.

The strain is characterized in that it does not produce a biological amine from one or more amino acid precursors selected from the group consisting of tyrosine, histidine, ornithine and lysine.

An embodiment of the present invention provides a probiotic preparation comprising, as an active ingredient, at least one selected from the group consisting of the strain, the culture of the strain, the concentrate of the culture, and the dried product.

An embodiment of the present invention provides a health functional food composition comprising, as an active ingredient, at least one selected from the group consisting of the strain, the culture of the strain, the concentrate of the culture, and the dried product.

An embodiment of the present invention provides a pharmaceutical composition comprising, as an active ingredient, at least one selected from the group consisting of the strain, the culture of the strain, the concentrate of the culture, and the dried material.

An embodiment of the present invention provides a beverage comprising at least one of a strain, a culture of the strain and a concentrate or a dried product of the culture as an active ingredient.

An embodiment of the present invention provides a health supplement containing, as an active ingredient, at least one of the strain, a culture of the strain, and a concentrate or a dried product of the culture.

According to the embodiments of the present invention, Lactobacillus plantarum KC28 strain has an anti-obesity effect, so that it can be used to suppress the occurrence of metabolic diseases caused by obesity and obesity in modern humans.

FIG. 1 is a graph showing the anti-adipogenic activity of the Lactobacillus plantarum KC28 strain of the present invention.
FIG. 2 is a graph showing the results of an experiment of bile resistance against Lactobacillus plantarum KC28 strain of the present invention. FIG.
FIG. 3 is a graph showing the results of the pH resistance test on the Lactobacillus plantarum KC28 strain of the present invention.
FIG. 4 is a graph showing the results of an experiment for the long-term fixation of Lactobacillus plantarum KC28 strain of the present invention.
5 is a graph showing the results of an experiment on the weight of the obesity-induced mouse for 12 weeks.
FIG. 6 is a graph showing the weight difference between the testis fat (A), subcutaneous fat (B), and visceral fat (C) extracted after completion of the mouse experiment.
FIG. 7 is a graph showing the results of measurement of intestinal permeability using Fluorescein isothiocyanate conjugated dextran (FITC-dextran) (Sigma-Aldrich).

Hereinafter, embodiments according to the present invention will be described in detail with reference to the accompanying drawings. However, the present invention is not limited or limited by the embodiments, and those skilled in the art can easily modify these embodiments. In addition, the same reference numerals shown in the drawings denote the same members.

Also, terminologies used herein are terms used to properly represent preferred embodiments of the present invention, which may vary depending on the viewer, the intention of the operator, or the custom in the field to which the present invention belongs. Therefore, the definitions of these terms should be based on the contents throughout this specification.

Experiments on the Lactobacillus plantarum KC28 strain of the present invention will be briefly described as follows.

Alpha-amylase inhibitory activity experiment

Recently, many studies for the development of obesity treatment drugs have been conducted, one of which is the α-amylase inhibition test. α-amylase is an enzyme that degrades the α-D- (1,4) -glucan bond of carbohydrates and is an important enzyme in carbohydrate metabolism. Currently, studies on hyperglycemia, diabetes, and insulin-related metabolic diseases require control of digestion and absorption of sugars, and studies on the inhibition of α-amylase enzyme activity have been conducted.

α- Glucosidase  Inhibition activity experiment

α-Glucosidase is an enzyme present in the small intestine epithelium, which acts as a disaccharide for the digestion and absorption of polysaccharides and disaccharide carbohydrates. Similar to α-amylase, inhibition of α-glucosidase activity may inhibit blood glucose elevation, and the activity against hyperglycemia and diabetes can be measured using this principle.

Pancreatic lipase inhibitory activity experiment

Pancreatic lipase acts as a key enzyme that breaks down triglyceride into 2-monoacylglycerol and fatty acid [Bitou, N., M. Nimomiya, T. Tsjita and H. Okuda. 1999. Screening of lipase inhibitors from marine algae. Lipids 34, 441-445]. Representative pancreatic lipolytic inhibitors are tetrahydrolipstatin (Orlistat), a derivative of lipstatin derived from Streptomyces toxitricini , which is known to be effective in inhibiting about 30% of the fat ingested [Drent, ML, et al., 1995. Orlistat RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int. J. Obes. 19, 221 -226.], And is currently also being marketed as a pharmaceutical product. Despite these benefits, however, tetrahydrolipstatin has been known to have side effects such as gastrointestinal disorders, hypersensitivity, biliary secretion, and lipid-soluble vitamin absorption inhibition. Recently, studies for the development of pancreatic lipolytic enzyme inhibitors from foods and natural products without side effects have been carried out.

Anti- adipogenic  activity experiment

Obesity caused by imbalance caused by high fat dietary intake is characterized by excessive accumulation of body fat and adipogenesis. The peroxisome proliferator activated receptor gamma (PPARγ), which plays a key role in the adipogenesis process of adipogenesis, is expressed in liver and adipose tissue in response to the ingested fat, which is necessary for differentiation into adipocytes and lipid synthesis And the genes that are expressed as proteins required for storage. In other words, anti-adipogenic activity is a method to measure the adipocyte differentiation activity as a fungus, and to measure how much fat cells are degraded by Oil Red O relative staining technique.

Bile tolerance and pH resistance test

Bile acid and pH, which are secreted from gastric juice and pancreas, are very important factors affecting the viability of microorganisms. Therefore, it is a method to measure how tolerant a microorganism is to the survival inhibition environment. We investigated the possibility of probiotics by investigating the resistance to artificial gastric juice and bile, and selecting and isolating strains with high activity and resistance.

Experiment of antibacterial activity

The antimicrobial activity was determined by Escherichia coli , Salmonella typhimurium , Staphylococcus aureus , Listeria monocytogenes , and the like. In the experiment, The better the deterrent against harmful strains, the better.

Gut permeability test

The foods we eat are digested by the intestinal microorganisms and enzymes, digesting and absorbing the nutrients in the small intestine. Until now, the intestines have been regarded as simply digesting and absorbing organs, but in fact, it is known that the intestines are the primary defense against harmful substances coming in from the outside, and that in various articles, the immune system is 70% to 80% The importance of intestinal health emerged. The normal intestine serves as a primary barrier to the mucous membranes, preventing harmful bacteria and harmful substances from entering the body. However, the Leaky gut is damaged by intestinal cells, and there is a microvilli on the inner wall of the small intestine. There are gaps in the binding sites of the cells, various kinds of harmful substances pass through them, and they are transported directly into the blood. It causes various diseases.

The microorganism isolation and identification process for the Lactobacillus plantarum KC28 strain of the present invention was performed by collecting and using kimchi having different types and regions from each of the present inventors and diluting it with a peptone diluent to obtain Bromcresol purple, And sodium azide were added to the transformed MRS medium. The culture broth was inoculated with 0.1 ml of each culture medium at 37 ° C for 48 hours. The transformant broth was purified from the transformed MRS medium and then transformed into yellow . The selected strains were plated on transformed MRS medium and then cultured aerobically to isolate pure strains. As a result of the identification of pure isolates, the strain was Gram positive bacillus and showed good growth regardless of presence or absence of oxygen and negative for catalase and motility. In addition, it did not grow at 15 and 45, and it was confirmed that it does not produce ammonia from gas and arginine from glucose and belongs to the genus of Lactobacillus .

The results of α-amylase, α-glucosidase, and pancreatic lipase inhibition on Lactobacillus plantarum KC28 strain of the present invention are shown in Table 1 below.

FIG. 1 is a graph showing the results of anti-adipogenic activity against Lactobacillus plantarum KC28 strain of the present invention, and Table 2 below shows the results of anti-adipogenic activity against Lactobacillus plantarum KC28 strain.

As shown in Fig. 1 and Table 2, it was found that the Lactobacillus plantarum KC28 strain inhibited the adipogenic activity of fat precursor cells by 36.99%. In other words, it can be seen that the Lactobacillus plantarum KC28 strain has an excellent adipocyte inhibitory activity.

All values or values were expressed as * when p <0.05 after Fisher's LSD test, ** when p <0.01, p <0.001 When *** is marked.

FIG. 2 is a graph showing the results of an experiment of bile resistance against Lactobacillus plantarum KC28 strain of the present invention. FIG.

More specifically, the Lactobacillus plantarum KC28 strain contains an MRS medium (with oxgall) containing 0.03% of oxgall and 0.05% of L-cysteine and 0.05% of L-cysteine -cysteine), all values (or values) were the mean ± standard deviation of three replicates, and * indicates the case of p <0.05 between with oxgall and without oxgall .

FIG. 3 is a graph showing the results of the pH resistance test on the Lactobacillus plantarum KC28 strain of the present invention.

More specifically, the survival rate of the Lactobacillus plantarum KC28 strain after three hours in hydrochloric acid at pH 2.0, 3.0, 4.0, and 6.4 is shown, and * is p <0.05 compared to the starting point (or start time) ** indicates the case of p <0.01, and *** indicates the case of p <0.001.

Table 3 below shows the results of the antibacterial activity test for Lactobacillus plantarum KC28 strain. The initial number of bacteria of Lactobacillus plantarum KC28 strain was 6.23 ± 0.40 × 10 ⁶ CFU / mL, and the result after 6 hours at 37 All values (or values) are mean ± standard deviation of three replicates.

Table 4 below shows the enzyme activity pattern for Lactobacillus plantarum K10 strain. In the standard color, a value of 0 to 2 is assigned, where 0 represents a negative number and 5 represents a maximum intensity reaction. The values from 1 to 4 indicate the intermediate response according to the intensity level, and the approximate activity can be estimated from the color intensity. 1 corresponds to 5 nanomolar, 2 corresponds to 10 nanomolar or less, 3 corresponds to 20 nanomolar or less, 4 corresponds to 30 nanomolar or less and 5 corresponds to 40 nanomolar or less liberation.

Table 5 below shows the antibiotic susceptibility of Lactobacillus plantarum KC28 strain, and it is shown that gentamycin, ampicillin, tetracycline, chloramphenicol, streptomycin, , Ciprofloxacin, penicillin G, and the like were confirmed to be resistant to antibiotics.

Specifically, each antibiotic was stair-diluted (1: 2) and mixed in MRS solid medium at a concentration of 0.025 to 64 / / ml. The minimum inhibitory concentration (MIC) was measured by inoculating Lactobacillus planta KC28 strain, which had been cultivated for 18 hours, into a solid medium containing the above antibiotics at a concentration of 1 × 10 ⁵ CFU, followed by culturing at 37 ° C. for 24 hours.

Biogenic amines are produced by the fermentation of foodstuffs and may vary depending on the type of microorganism or chemical and physical conditions. Biomolecules produced in fermented foods are an important criterion for choosing a food-engineered strain because it can cause food poisoning or allergic reactions.

In order to confirm the formation of biomolecules of the strain of the present invention, the strain grown for 16 hours in the MRS liquid medium, 37, was transferred to a special medium according to Bover-Cid and Holzapfel (1999) and cultured at 37 for 48 hours.

MRS liquid medium supplemented with amino acid precursors of each of tyrosine, histidine, ornithine and lysine was prepared and the biomolecules (tyramine, histamine (histamine), putrescine and cadaverine) were produced. Specifically, 1% of the isolated Lactobacillus plantarum strain was inoculated into the MRS liquid medium supplemented with 0.1% of the amino acid precursor, and then cultured for 5-10 times to activate the decarboxylase. The concentration of dextrinase enzyme medium [tryptone 0.5%, yeast extract 0.5%, cocoon extract 0.5%, sodium chloride 0.5%, glucose 0.25%, tween-80 0.05%, magnesium sulfate 0.02%, manganese sulfate 0.005% 0.2% of salt, 0.001% of thiamine, 0.2% of K2PO4, 0.01% of calcium carbonate, 0.005% of pyridoxal-5-phosphate, 1% of amino acid, 0.006% of bromocresol purple, 2% was mixed with distilled water and adjusted to pH of 5.3], and then incubated at 37 for 24 to 48 hours to determine the color change to purple.

The bromocresol purple in the decarbonated enzyme medium is yellow at pH 5.2 but turns purple as the pH rises to 6.8. Therefore, the production of bio-amines can be confirmed by using a substance that turns purple when the pH rises due to the formation of bio-amines.

As shown in Table 6, putrescine, tyramine, histamine, and Kade were found to be effective for the biosynthesis of Lactobacillus plantarum KC28. All of the cadaverine was confirmed by negative. From these results, it was confirmed that the strain of the present invention has no bio-amine generating ability capable of inducing an irritable immune response.

FIG. 4 is a graph showing the results of an experiment for the long-term fixation of Lactobacillus plantarum KC28 strain of the present invention.

More specifically, it shows the adhesion ability to HT-29 cells together with Lactobacillus lambusus GG probiotic strain, and all values (or values) are mean ± standard deviation of three replicates, ** indicates the case of P < 0.05 compared with the control (control).

FIG. 5 is a graph showing the results of an experiment on the weight of the obesity-induced mouse for 12 weeks, together with other lactic acid bacterial strains.

More specifically, ND is a normal chow fat diet group, HFD is an IF (intermediate fat) diet group, Xen is IF + xenical administration group, LGG is IF + LGG administration group, 299v is IF + KC3 is an IF + KC4 administration group, KC4 is an IF + KC4 administration group, K10 is an IF + K10 administration group, K50 is an IF + K50 administration group, KC28 is an IF + KC28 administration group, LR86 is the IF + LR86 administration group, and KID7 is the IF + KID7 administration group. The values were expressed as mean and standard deviation. For the IF diet, the control diet and mixed diet groups were marked with * when p <0.05 after Fisher's LSD test, and ** when p <0.01 , and *** when p <0.001.

FIG. 6 is a graph showing the weight difference between the testis fat (A), subcutaneous fat (B) and visceral fat (C) extracted after completion of the mouse experiment, together with other lactic acid bacterial strains.

More specifically, ND is a normal chow fat diet group, HFD is an IF (intermediate fat) diet group, Xen is IF + xenical administration group, LGG is IF + LGG administration group, 299v is IF + KC3 is an IF + KC4 administration group, KC4 is an IF + KC4 administration group, K10 is an IF + K10 administration group, K50 is an IF + K50 administration group, KC28 is an IF + KC28 administration group, LR86 is the IF + LR86 administration group, and KID7 is the IF + KID7 administration group. The values were expressed as mean and standard deviation. For the IF diet, the control diet and mixed diet groups were marked with * when p <0.05 after Fisher's LSD test, and ** when p <0.01 , and *** when p <0.001.

FIG. 7 is a graph showing the results of measurement of intestinal permeability using Fluorescein isothiocyanate conjugated dextran (FITC-dextran) (Sigma-Aldrich), together with other Lactobacillus plantarum strains.

More specifically, ND is a normal chow fat diet administration group, HFD is an IF (intermediate fat) diet administration group, LGG is IF + LGG administration group, 299v is IF + 299v administration group, K10 is IF + K10 K50 is an IF + K50 administration group, KC28 is an IF + KC28 administration group, and K259 is an IF + K259 administration group. The values were expressed as mean and standard deviation. For the IF diet, the control diet and mixed diet groups were marked with * when p <0.05 after Fisher's LSD test, and ** when p <0.01 , and *** when p <0.001.

Specifically, the mucosal cells of the intestine are a single cell layer, but the cells are attached to each other with tight junctions. However, due to the induction of obesity and changes in the fibrinogen composition, the gap between these cells is loosened or damaged, Leaky gut syndrome is the result of the leakage of polymeric materials into the intestinal tract or the introduction of polymeric substances directly into the bloodstream. If the permeability increases for any reason, the pathogen, endotoxin (broken cell wall tissue of gram negative strain), and inflammatory molecules enter the bloodstream and intestinal endotoxemia occurs. However, lactic acid bacteria also have the effect of reducing the intestinal permeability, and combine with intestinal mucosa to form a clustered membrane, preventing harmful bacteria from damaging the intestinal mucosa. Therefore, FITC-dextran (44 mg / 100 g mouse weight) was fed to mice (N = 6-9) fed with a 15-week mixed diet on the basis of bio-protocol, As can be seen from Fig. 7, the Lactobacillus plantarum KC28 strain was strain-specific and the intestinal permeability was significantly lower than that of the control (HFD), and it was significantly higher than that of Lactobacillus lambosus GG probiotic strain And the low permeability was confirmed.

In addition, the present invention may provide a probiotic preparation comprising at least one member selected from the group consisting of the Lactobacillus plantarum KC28 strain, the culture of the strain, the concentrate of the culture and the dried product as an active ingredient.

The probiotic agent can be prepared and administered in various formulations and methods according to methods known in the art. For example, the Lactobacillus plantarum KC28 strain of the present invention, a culture thereof, a concentrate of the culture broth or a dried product thereof may be mixed with a carrier commonly used in the pharmaceutical field to prepare powders, liquids and solutions, May be formulated and administered in the form of tablets, capsules, syrups, suspensions or granules, and the like. Examples of the carrier include, but are not limited to, binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, coloring matters and fragrances. The administration dose can be appropriately selected depending on the degree of absorption of the active ingredient in the body, the inactivation rate, the excretion rate, the age, sex, strain, condition and severity of the disease.

The present invention also provides a health functional food composition for preventing or ameliorating obesity comprising at least one member selected from the group consisting of Lactobacillus plantarum KC28, a culture of the strain, a concentrate of the culture, and a dried product as an active ingredient to provide.

The health functional food composition of the present invention may be prepared in any one form selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and rings. The health functional food composition according to the present invention may be formulated in the form of a powder, a liquid, a tablet, a soft capsule, a granule, a tea bag, an instant tea or a drink by incorporating the Lactobacillus plantarum KC28 strain or the like as an active ingredient . The content of Lactobacillus plantarum KC28 strain as an active ingredient can be suitably determined according to the intended use (for prevention or improvement). In addition, the food composition according to the present invention may contain, in addition to the Lactobacillus plantarum KC28 strain, other components that can give rise to a synergistic effect on the main effect, within the range not impairing the intended main effect of the present invention It is acceptable.

The food composition formulated in this form can be added directly to the food or used together with other food or food ingredients, and can be suitably used according to conventional methods. Examples of food products include dairy products including drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, , Dairy products and dairy products, and all health functional foods in the ordinary sense are included.

When the food composition of the present invention is a beverage, it contains Lactobacillus planta KC28 strain as an essential ingredient at the indicated ratio, and there are no particular restrictions on other ingredients used for the purpose of producing other beverages. Flavoring agents, natural carbohydrates and the like as additional components. Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors and synthetic flavors and the like can be used as the flavors other than those described above. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition, the food composition of the present invention can be used as a food composition containing various nutrients, vitamins, minerals (electrolytes), synthetic flavors and flavors such as natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the inventive food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not so important, it is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of Lactobacillus plantarum KC28 strain of the present invention.

Further, the present invention provides a pharmaceutical composition for preventing or treating obesity, which comprises at least one selected from the group consisting of the above-mentioned Lactobacillus plantarum KC28 strain, the culture of the strain, the concentrate of the culture and the dried product as an active ingredient do.

The throughput of the pharmaceutical composition for preventing or treating obesity used in the present invention should be a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dose level will vary depending on the species and severity, The type of virus being infected, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs and other well known factors in the medical field. Effective amounts may vary depending on the route of treatment, the use of excipients, and the likelihood of use with other agents, as will be appreciated by those skilled in the art.

The pharmaceutical composition for the prevention or treatment of obesity of the present invention may be manufactured into pharmaceutical formulations using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. In the preparation of the formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container.

Therefore, the pharmaceutical composition for preventing or treating obesity of the present invention can be formulated into oral formulations, external preparations and patches such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols according to a conventional method And may further comprise suitable carriers, excipients or diluents conventionally used in the manufacture of the compositions.

Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used.

In addition, the Lactobacillus lactobacillus plantarum KC28 strain described herein may be contained in various types of products such as health food, beverages, fermented foods including fermented dairy products, and the like.

Claims (7)

Lactobacillus plantarum KC28 strain (accession number: KCTC13377BP) having an anti-obesity effect.
The method according to claim 1,
Wherein the strain does not produce a biological amine from one or more amino acid precursors selected from the group consisting of tyrosine, histidine, ornithine, and lysine.
A probiotic preparation comprising at least one member selected from the group consisting of a strain according to any one of claims 1 to 2, a culture of the strain, a concentrate of the culture and a dried product as an active ingredient.
A health functional food composition comprising, as an active ingredient, at least one selected from the group consisting of a strain of any one of claims 1 to 2, a culture of the strain, a concentrate of the culture, and a dried product.
A pharmaceutical composition comprising, as an active ingredient, at least one selected from the group consisting of a strain of any one of claims 1 to 2, a culture of the strain, a concentrate of the culture, and a dried product.
A beverage comprising at least one of the strains of any one of claims 1 to 2, a culture of the strain and a concentrate or a dried product of the culture as an active ingredient.
A health supplement containing at least one of the strains of any one of claims 1 to 2, a culture of the strain and a concentrate or a dried product of the culture as an active ingredient.

Images